AGIO — Agios Pharmaceuticals, Inc.

Open full analysis

Chart, dilution, float and news for AGIO in the TickerWise workspace.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Company profile

• Sector: Healthcare
• Industry: Biotechnology
• Country: US
• Exchange: NASDAQ
• Employees: 486
• Website: https://www.agios.com

Latest SEC filings for AGIO

• 2026-10-234
• 2026-08-03SCHEDULE 13G/A
• 2026-07-3010-Q
• 2026-07-308-K
• 2026-07-02SCHEDULE 13G
• 2026-06-18S-8
• 2026-06-188-K
• 2026-04-2910-Q
• 2026-04-298-K
• 2026-03-26SCHEDULE 13G/A

Latest AGIO news

• 2026-10-08Agios to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5 at 8:00 a.m. ET Read article
• 2026-10-06AGIO Stock Sinks 29% in Three Months: Here's What You Need to Know Read article
• 2026-10-02Agios' Growth Story Hinges on Mitapivat's Commercial Expansion Read article

Open full analysis

Educational tool only — not investment advice.